Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate
نویسندگان
چکیده
منابع مشابه
Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide.
BACKGROUND The efficacy of and overall survival associated with metastatic castration-resistant prostate cancer (CRPC) treatments rely on patients' consistent adherence to the recommended dosage regimens. OBJECTIVES To evaluate treatment patterns and patient adherence to abiraterone acetate or enzalutamide therapy in real-world practice, and to examine the factors that may be associated with ...
متن کاملAbiraterone Acetate Withdrawal Syndrome: Does It Exist?
In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy. We report the case of a patient who experienced a confirmed PSA decrease of ≤50% after stopping AA, mimicking an antiandrogen withdrawal syndrome.
متن کاملU.S. FDA Approval Summary: Abiraterone Acetate
1 CCR Perspectives in Drug Approval Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary Paul G. Kluetz, Yang-Min Ning, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Debasis Ghosh, Robeena Aziz, Todd Palmby, Elimika Pfuma, Jeanne Fourie Zirkelbach, Nitin Mehrot...
متن کاملAbiraterone acetate: redefining hormone treatment for advanced prostate cancer.
Prostate cancer has long since been recognised as being hormonally driven via androgen receptor signalling. Abiraterone acetate (AA) is a rationally designed CYP17 inhibitor that blocks the conversion of androgens from non-gonadal precursors effectively, thus reducing testosterone to undetectable levels. AA has recently been proved to extend survival for men with metastatic castration-resistant...
متن کاملAbiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
Ductal adenocarcinoma of the prostate is a rare histological variant that only represents <1% of prostate tumors. This histological variant has several important clinical implications with respect to their evolution, clinical prognosis, and treatment. We report the case of a 64-year-old patient with ductal adenocarcinoma of the prostate, which progresses to castration-resistant prostate cancer,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Oncology
سال: 2018
ISSN: 0732-183X,1527-7755
DOI: 10.1200/jco.2018.79.3182